A prospective cohort shows that hormone patterns during minipuberty can help identify ovarian activity in Turner syndrome.
In real-world patients with mHSPC, a PSA cutoff of 0.2 ng/mL after 6 to 12 months of intensified hormone therapy predicts survival outcomes. An absolute PSA level of 0.2 ng/mL or more at 6 to 12 ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...